GSK’s latest acquisition adds a next-generation pulmonary hypertension candidate with early indications that it may affect metabolic health and aging.
In a deal that quietly has major implications, the global health company GSK completed the purchase of 950 million US dollars 35Pharma IncMontreal-based clinical stage biotechnology focused on protein therapy.
This is a $950 million move with more than one objective and direct pipeline expansion. Its lead is HS235, a drug candidate for pulmonary hypertension (PH), a life-shortening condition marked by high blood pressure in the lungs (1). Look a little closer, this purchase becomes a bet on how chronic conditions interact with our age.
Because PH is not just a lung problem. It is a systemic system. It stresses the heart, disrupts oxygen flow, and often overlaps with metabolic issues like obesity and insulin resistance. An estimated 82 million people worldwide live with some form of it, but treatment options remain limited and survival rates remain dismal.
If you ask clinicians what makes treating PH so difficult, the answer is often about trade-offs. Available medications can help open up blood vessels in the lungs, relieve pressure, and improve symptoms. However, they can also cause risks – bleeding, fluid around the heart or changes in blood composition – that make long-term management difficult. In some cases, treating one problem causes another.
The HS235 is designed to navigate around these compromises. Rather than dealing broadly with biological signals, it requires a more targeted approach that focuses on the activin receptor signaling pathway, a mechanism that already plays a role in PH. Consider configuring one number instead of changing every switch in the control room. The goal is clear: keep what works, avoid what doesn’t.
With greater selectivity, HS235 could potentially reduce the risk of side effects that limit current treatments. In chronic diseases, where patients take drugs for years, this kind of improvement can make the difference between a treatment that is theoretically effective and one that people actually live with.
An unexpected angle of metabolism
In early clinical observations, HS235 showed signs of impacting metabolic health. Patients lost selective fat mass, maintained lean muscle mass, and improved insulin sensitivity. These are not trivial results; they address some of the persistent challenges in the aging population.
Obesity, muscle wasting and insulin resistance not only co-exist with diseases like PH; they often accelerate them, so therapy that addresses both vascular and metabolic health can be a multidisciplinary intervention.
Of course, it is early. These findings need to be confirmed in larger trials, but there is a signal of widespread change in how drugs are designed to alter the biological environment that allows this condition to develop.
The financial logic behind the purchase is clear. The global pulmonary hypertension treatment market is expected to reach $18 billion by 2032, with new approaches such as activin signaling inhibitors capturing a significant share.
HS235 will sit within GSK’s Respiratory, Immunology and Inflammation (RI&I) pipeline, an area increasingly focused on key drivers of chronic diseases such as inflammation and fibrosis, which cut across organs and conditions.
“HS235 is an important addition to our RI&I pipeline that continues to address the inflammatory and fibrotic drivers underlying multiple chronic diseases,” said Kaivan Havandi, SVP, Head of Respiratory, Immunology and Inflammation and Head of Translational and Developmental Sciences at GSK. Morningstar (2).
“With approximately 82 million patients currently living with PH in its various forms, (a) the high burden of disease associated with this disease and the associated poor prognosis, with a low five-year survival rate, we are committed to advancing this novel and differential option to expand the currently limited treatment.”
Where can this lead?
Proof-of-concept trials are expected to begin soon in two forms of the disease: pulmonary arterial hypertension (PAH) and PH associated with heart failure with preserved ejection fraction (PH-HFpEF). Both sit at the crossroads of cardiovascular decline and aging—which is exactly what makes this acquisition worth watching.
When it enters the tube as a pulmonary drug, its potential reach extends beyond the lungs. If HS235 achieves both safety and metabolic benefits, it could reinforce a growing idea in longevity science: that the most valuable treatments are not for diseases in isolation, but for the shared pathways that connect them.
In other words, the future of chronic disease treatment may look like a network approach, where improvements in one system lead to improvements in others.
For GSK, the $950 million price tag provides a promising asset. It raises a bigger question for the field: What happens when drugs developed for a disease begin to quietly improve the biology of aging itself? This is where this story moves to something closer to change.
Photo courtesy of GSK
(1) https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-35pharma-inc/
(2) https://global.morningstar.com/en-gb/news/alliance-news/1776245632291968600/gsk-completes-purchase-of-canadas-35pharma-for-usd950-million
